The present invention provides compositions and methods that promote wound healing in a subject with a cutaneous injury. In particular, the present invention provides systemic and/or local administration of one or more compositions that cause ganglioside depletion (e.g., glucosylceramide synthase (GCS) inhibitors) for the treatment of cutaneous wounds.

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.

Treatment of fibrosis and fibrotic diseases, disorders, and conditions, and associated methods, compositions, formulations and articles.

Compositions, systems, devices, and methods for performing precise chemical treatment of tissues are disclosed. Systems, devices, and methods for administering a chemical agent to one or more a precise regions within a tissue mass are disclosed. Compositions, systems, devices, and methods for treating targeted regions within a tissue mass are disclosed. Systems, devices, and methods for identifying, localizing, monitoring neural traffic in the vicinity of, quantifying neural traffic in the vicinity of, and mapping neural traffic near targeted regions within a tissue mass are disclosed.

To provide means for efficient growth of epithelial cells capable of being used to manufacture regenerated hair follicle germs. Provided are a culture medium for growth of epithelial cells capable of being used to manufacture regenerated hair follicle germs, the culture medium comprising basal medium and at least (1) through (3), below: and a method for growing the epithelial cells using the culture medium: (1) at least one species of BMP inhibitor: (2) at least one species of fibroblast growth factor: and (3) at least one species of sonic hedgehog (SHH) and/or SHH agonist.

A tubular nonwoven structure as an active agent carrier (“sleeve”) for the atraumatic treatment of hollow organs, in particular applicable via a balloon catheter, as well as a method for the production thereof, wherein the sleeve is folded about a longitudinal sleeve axis in an initial state and is unfoldable in a final state for attachment to an inner wall of a hollow organ, the tubular sleeve is formed of first biodegradable polymer nanofibers and the folding of the sleeve is directed as pleating about a longitudinal sleeve axis, a medicinal active agent is incorporated into the first polymer nanofibers and/or is arranged in interspaces between the polymer nanofibers, and the first polymer fibers are formed such that the polymer fibers degrade over a period of 2 weeks to 3 months so that the active agent can be delivered to a hollow organ wall in this period of time.

The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1β) receptor antagonist (IL-1Ra), such as anakinra. The IL-1Ra can be administered topically to a chronic wound including a diabetic ulcer.

This disclosure relates to sclerostin inhibitors for use in ossification, and methods related thereto. In certain embodiments, the disclosure relates to placing sclerostin inhibitors in graft compositions for forming bone. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a graft composition disclosed herein optionally comprising a growth factor such as BMP or recombinant vector expressing the same in a subject such as at a desired site of bone or cartilage growth.